IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 317 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 1.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,956,746 | +10.6% | 197,460 | +0.1% | 0.01% | +11.1% |
Q2 2023 | $8,096,572 | +128111.7% | 197,333 | +11.7% | 0.01% | +12.5% |
Q1 2023 | $6,315 | +1.2% | 176,685 | +7.0% | 0.01% | 0.0% |
Q4 2022 | $6,238 | -99.9% | 165,163 | +6.1% | 0.01% | -20.0% |
Q3 2022 | $6,887,000 | +20.4% | 155,714 | +0.8% | 0.01% | +25.0% |
Q2 2022 | $5,720,000 | +15.6% | 154,502 | +15.7% | 0.01% | +33.3% |
Q1 2022 | $4,947,000 | +16.3% | 133,560 | -4.4% | 0.01% | +20.0% |
Q4 2021 | $4,253,000 | -8.4% | 139,749 | +1.0% | 0.01% | -16.7% |
Q3 2021 | $4,641,000 | -16.6% | 138,363 | -0.9% | 0.01% | -14.3% |
Q2 2021 | $5,568,000 | -14.2% | 139,585 | -3.3% | 0.01% | -22.2% |
Q1 2021 | $6,492,000 | -24.4% | 144,406 | -4.9% | 0.01% | -25.0% |
Q4 2020 | $8,583,000 | +17.1% | 151,811 | -1.7% | 0.01% | +9.1% |
Q3 2020 | $7,328,000 | -22.2% | 154,445 | -3.4% | 0.01% | -31.2% |
Q2 2020 | $9,422,000 | +42.9% | 159,805 | +14.6% | 0.02% | +14.3% |
Q1 2020 | $6,593,000 | -22.8% | 139,451 | -1.3% | 0.01% | 0.0% |
Q4 2019 | $8,535,000 | +3.3% | 141,284 | +2.5% | 0.01% | -6.7% |
Q3 2019 | $8,259,000 | -7.3% | 137,861 | -0.6% | 0.02% | -11.8% |
Q2 2019 | $8,913,000 | -22.1% | 138,683 | -1.6% | 0.02% | -22.7% |
Q1 2019 | $11,444,000 | +49.3% | 140,983 | -0.6% | 0.02% | +29.4% |
Q4 2018 | $7,664,000 | +1.0% | 141,776 | -3.6% | 0.02% | +13.3% |
Q3 2018 | $7,588,000 | +21.5% | 147,113 | -1.8% | 0.02% | +15.4% |
Q2 2018 | $6,244,000 | -3.8% | 149,846 | +1.7% | 0.01% | -7.1% |
Q1 2018 | $6,494,000 | -14.9% | 147,334 | -2.9% | 0.01% | -12.5% |
Q4 2017 | $7,634,000 | -2.3% | 151,775 | -1.5% | 0.02% | -5.9% |
Q3 2017 | $7,813,000 | -2.8% | 154,100 | -2.5% | 0.02% | -5.6% |
Q2 2017 | $8,042,000 | +24.9% | 158,084 | -1.3% | 0.02% | +20.0% |
Q1 2017 | $6,440,000 | -12.8% | 160,198 | +3.7% | 0.02% | -21.1% |
Q4 2016 | $7,388,000 | +40.9% | 154,460 | +7.9% | 0.02% | +35.7% |
Q3 2016 | $5,245,000 | +64.9% | 143,141 | +4.8% | 0.01% | +55.6% |
Q2 2016 | $3,180,000 | -40.1% | 136,547 | +4.2% | 0.01% | -43.8% |
Q1 2016 | $5,307,000 | -34.6% | 131,043 | +0.1% | 0.02% | -38.5% |
Q4 2015 | $8,110,000 | – | 130,953 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BB BIOTECH AG | 6,529,838 | $404,393,000 | 11.39% |
DOWLING & YAHNKE LLC | 676,379 | $41,888,000 | 5.27% |
Opus Point Partners Management, LLC | 102,459 | $6,345,000 | 4.19% |
WILLIAM HARRIS INVESTORS INC | 230,443 | $14,271,000 | 3.43% |
PINNACLE ASSOCIATES LTD | 1,690,263 | $104,678,000 | 2.20% |
MESSNER & SMITH THEME VALUE INVESTMENT MANAGEMENT LTD /CA/ | 21,298 | $1,319,000 | 2.11% |
Sonora Investment Management, LLC | 126,763 | $7,850,000 | 2.04% |
Virtus ETF Advisers LLC | 10,447 | $647,000 | 1.78% |
Apex Capital Management | 1,020,096 | $63,175,000 | 1.41% |
PERKINS CAPITAL MANAGEMENT INC | 19,900 | $1,232,000 | 1.32% |